Drugs & Targets EC approves Keytruda + trastuzumab + chemo for first-line treatment of GEJ cancer September 08, 2023Vol.49 No.33
FDA, NCI align to simplify clinical research, producing a model “pragmatic” registration trial in NSCLC December 02, 2022Vol.48 No.43By Jacquelyn Cobb, Matthew Bin Han Ong and Paul Goldberg
Conversation with The Cancer Letter Roy Herbst: I hope Pragmatica-Lung will become the norm December 02, 2022Vol.48 No.43By Jacquelyn Cobb and Paul Goldberg
Conversation with The Cancer Letter Ellen Sigal: Pragmatica-Lung may be a model for other trials that are unnecessarily complex December 02, 2022Vol.48 No.43By Matthew Bin Han Ong
Drugs & Targets Lynparza receives positive CHMP opinion for metastatic, castration-resistant prostate cancer November 18, 2022Vol.48 No.42
Drugs & Targets Portage Biotech, Merck to collaborate on clinical trial November 11, 2022Vol.48 No.41
Drugs & Targets Health Canada approves Merck’s Keytruda as post-surgery monotherapy in kidney cancer patients October 14, 2022Vol.48 No.37
Clinical Roundup Long-term data from AstraZeneca/Merck’s Lynparza shows survival benefit in ovarian cancer September 16, 2022Vol.48 No.33
